Samples of metastatic prostate cancer to bone are difficult to obtain. The aim of this study was to compare the results of bone marrow aspirate and trephine biopsy for obtaining metastatic hormone-refractory prostate cancer (HRPC) samples using previous diagnostic planar 99 m Tc-HDP bone scans to guide the procedure. All samples taken were for the purposes of research and molecular studies on HRPC. Twenty patients with HRPC had bone marrow aspirate and trephines taken from lesions in the posterior superior iliac spine or sacro-iliac region when shown on diagnostic 99 m Tc-HDP bone scans. Three patients also underwent plain X-ray, 18F-positron emission tomography bone scan, pelvic MRI scan and 99 m Tc nanocolloid bone marrow scans. These images were used to assess if the extra imaging information provided, such as three-dimensional localisation of the bone metastases, was of value for target bone metastases. Cancer cells were obtained in 15/20 (75%) cases in which a trephine biopsy was attempted and 0/20 of cases in which a bone marrow aspiration was attempted. The additional information provided by the range of other imaging investigations was of little benefit in obtaining tumour samples, but did suggest why negative biopsies were obtained in some cases after targeting with planar bone scans. We recommend the use of bone marrow trephine biopsy alone, guided by previous diagnostic 99 m Tc planar bone scan as a practical method to obtain prostate cancer cells from bone metastases. Keywords: 99 m Tc-bone scan; 99 m Tc-nanocolloid bone marrow scan; bone marrow aspiration; bone marrow trephine; Fluorine18 positron emission tomography bone scan; hormone-resistant prostate cancer; pelvic magnetic resonance imaging scan
Introduction
Prostate cancer is a common malignancy amongst men in the Western World. In 1993 in England and Wales 17 210 new cases were diagnosed and during the period 1971 -1993, the incidence of the disease increased by 179%. 1 Early stage disease may be cured by prostatectomy or radiotherapy but a proportion of these patients will relapse with incurable disease. In addition, a significant proportion of patients present with metastatic disease. Bone metastases are a common cause of morbidity and mortality representing a considerable burden for the Health Service. Better therapies for metastatic disease are required. Relatively little is known about the mechanism of the osteoblastic and sclerotic bone metastases produced by prostate cancer. The molecular mechanisms that underlie bone metastases and the development of hormone-insensitive disease at this and other sites need to be understood.
Diagnostic bone marrow aspiration and trephine biopsy are seldom done at disease relapse since the widespread introduction of radionuclide bone scanning. This, together with the difficulty in working with bony samples that contain a mixture of hard and soft tissues 2 has resulted in bone metastases being relatively understudied (compared with prostatic tissue obtained during therapeutic transurethral resection).
The bone marrow aspirate and trephine samples in this study were obtained for the purpose of molecular studies on androgen receptor immunohistochemical expression, androgen receptor gene amplification and comparative genomic hybridisation studies in hormone-refractory prostate cancer (paper currently in preparation).
This study resulted from two observations. The first was the paucity of published information on our proposed method of targeting bone metastases for biopsy in advanced carcinoma of the prostate using isotope bone scans. 3 -6 The second was our observation that bone marrow aspirates from patients with bone metastases from hormone-refractory prostate cancer patients rarely contained cancer cells.
Patients and methods

Patients
Over an 11-month period, eligible patients were recruited from outpatient clinics or during inpatient admission. Hormone-refractory disease was defined as disease progression (requiring a change in therapy) after at least one previous hormonal manipulation and associated with a rising serum prostate specific antigen (PSA). Patients with previous radiotherapy to the sacro-iliac region were excluded from the study on the basis of possible confounding cytogenetic changes due to the radiation.
Methods
The project was given approval by the Local Research Ethics Committee. For all patients the previous history and diagnostic planar Technetium-99 m hydroxymethylene diphosphonate (750 MegaBecquerels 99 m Tc-HDP) bone scans (hereafter called bone scan) were reviewed for the presence of bone metastases affecting the sacroiliac region that would be suitable for biopsy. Bone scans had to have been performed within 1 y. Comprehensive training in bone aspiration and trephine biopsy was given by the haematology service prior to undertaking the collection of study cases. All samples were taken by RB using local anaesthetic at a site selected with direct reference to the bone scan. The posterior superior iliac spine was located and the site of biopsy chosen with reference to this. Clinical tenderness to palpation was used to help identify metastatic sites if apparent. If the proposed area chosen was not able to be safely biopsied (inaccessible to the aspiration needle), then the posterior superior iliac spine was used instead.
Bone marrow aspirates were taken first, using a 15G Marrowgauge TM needle (Rocket Medical, Watford, UK). Bone marrow trephine(s) were then taken with a BectonDickinson Bone Marrow Biopsy needle (Becton-Dickinson, NJ, USA). Haemostasis was achieved and analgesia given if required.
Diagnostic bone marrow aspirate slides were made using the standard smear technique and sent to the diagnostic haematology service for reporting. Bone marrow trephines were immediately placed in formalin -saline and sent for routine overnight acid decalcification and subsequent histological assessment by the histopathology service. Standard stains and immunohistochemistry (PSA, prostate specific acid phosphotase (PSAP) and the cytokeratin markers CAM 5.2 and MNF116) were performed on all samples. After eight patients had undergone aspirate and trephine biopsies, half of the aspirate sample slides were also sent for immunocytochemistry for PSA and CAM 5.2.
In addition to the standard method of bone scans described, three patients also agreed to have whole body 18-Fluorine (200 MegaBecquerels) positron emission tomography bone scans (hereafter called 18F PET), 99 m Tc (375 MegaBecquerels) nanocolloid bone marrow scans (hereafter called nanocolloid bone marrow scan) and MRI scans of the pelvis (including short tau inversion recovery (STIR) sequences for marrow images). The aim of these scans was to either look at the pattern of disease in three dimensions or to look at changes in the bone marrow adjacent to known metastases. A specific ARSAC licence was obtained for the three patients. Plain X-rays of the pelvis were also performed on all patients. All imaging studies were completed prior to each patient undergoing bone marrow aspiration and biopsy.
Spearman log rank test was used to correlate the number of lesions on the bone scan with the serum PSA values.
Results
Twenty of 29 patients approached agreed to participate (69%, see Table 1 ). One patient had co-existent chronic myeloid leukaemia. The mean age of patients was 71 y and the number of previous treatments for prostate cancer ranged from one to six (covering most curative and palliative modalities used for prostate cancer treatment). Patients had undergone the treatments listed in Table 1 prior to bone marrow aspiration and trephine biopsy. Previous therapy was usually systemic in nature and intended to provide palliation. Only four patients had originally been treated radically. The majority of patients (12/20) had presented with metastatic disease (M1).
All patients had abnormally elevated serum PSA levels; with a range from 19 to 3306 ng/ml. Anaemia was a common finding on the full blood count (FBC) with 14/20 patients having a haemoglobin below the laboratory reference range of 13 g/dl. However, only 3/ 20 patients had a white cell count (WBC) below 4610 9 /l and only a single patient had an abnormally low platelet count (patient 10, 114610 9 /l). Two patients with a low WBC also had a low haemoglobin level suggesting possible marrow failure, but in both cases the bone marrow aspirates were negative and the trephine biopsies showed less than a 5% tumour cell infiltrate. The range of lesions visible on the AP planar bone scans for all patients ranged from seven to over 50. In addition, one patient had a 'superscan' (widespread tracer uptake with no renal tracer excretion visible at the time of scanning). The two patients with blood counts suggestive of some marrow failure did not have very high hot spot counts on the bone scans. We could find no correlation between the level of serum PSA and the number of hot spots on the bone scan (r ¼ 0.12, Spearman log rank test).
The results of the aspiration and biopsies are shown in Table 2 . In two cases no material was obtained due to a dry tap on aspiration and a failed trephine biopsy, secondary to sclerotic bone (unable to be penetrated by the trephine needle). In the remaining 18 cases, a suitable bone marrow trephine was obtained. For three of the 18 trephine biopsies (17%) a normal marrow sample with no evidence of tumour deposits was obtained. Fifteen of the 18 successful trephines (83%) contained metastatic tumour. In one of these samples only a single microscopic focus of disease was seen on immunohistochemistry.
Of 18 attempts at bone marrow aspiration, no material was aspirated in six due to a dry tap. These failures were associated with either diffuse tumour infiltration in the trephine biopsy (4/6) or also had an unsuccessful trephine biopsy (2/6). Ten of the aspirates contained sufficient particulate material to assess. In one case suspicious cells were seen, but this was associated with a normal trephine biopsy. In the remaining cases no evidence of tumour cells was seen. Four aspirate samples were haemodilute and sub optimal for assessment. One of these was reported as containing possible occasional suspicious cells but the trephine showed low levels of tumour infiltrate ( < 5%).
Of nine cases where aspirate slides were also sent for immunocytochemistry (PSA and CAM 5.2), no evidence of tumour infiltrates were seen, in complete agreement with the haematological assessment.
The bone marrow sampling was generally well tolerated by patients with no major complications. One patient had a pre-syncopal episode that settled with a short period of bed rest after the procedure. The majority of patients were already on compound analgesics, non-steroidal anti-inflammatory drugs or opiates because of bone metastases prior to the aspirate and trephine biopsies. Local pain after the procedure was uncommon and patients seldom required extra analgesia. In three out of the 20 cases the patient would have declined to undergo a similar procedure again, two of these cases were in patients with a failed aspirate and trephine due to sclerotic bone.
For the three patients who underwent the other types of bone imaging (plain X-ray, 18F PET bone scan, nanocolloid bone marrow scans and MRI scans of the pelvis), the target lesion was successfully identified in all three patients on the PET bone scans and MRI scans of the pelvis, as in Figure 1B and C. In no case did the nanocolloid bone marrow scan identify the target lesions in the sacro-iliac region (see Figure 2A) . In only one patient did the nanocolloid bone marrow scan identify any bone marrow abnormality (a solitary accumulation defect which matched a known hot spot on the diagnostic bone scan, data not shown). Of the three plain X-rays taken, an abnormality at the site of the target lesion was seen in one case (data not shown).
The corresponding nanocolloid bone marrow scan and pelvic X-ray for the patient in Figure 1 are shown in Figure 2 .
Discussion
The detection of metastases within bone marrow by needle aspiration was first reported in 1936 and included a patient with metastatic carcinoma of the prostate. 7 Specific studies on the bone marrow changes in prostate cancer then began to appear in the 1940s and 1950s. 8, 9 Early studies were mainly in the context of diagnosis and staging, particularly with reference to diagnosing occult bone metastases radiologically, and to try and prevent unnecessary radical surgery. 10 As new diagnostic techniques became available, such as improvements in chemical pathology (eg bone marrow acid phosphatase) 4 histopathology techniques (eg immunohistochemistry) 11 and molecular biology (eg polymerase chain reaction) 12 further studies have continued to been published.
Bone and bone marrow samples are inherently more difficult to work with than some other tissue types, due to the mixture of hard and soft material and the need for acid or EDTA decalcification. Tissue such as prostate gland, removed at transurethral resection, is justified on diagnostic and therapeutic grounds, as well as providing material for study. Bone marrow aspiration and trephine biopsy is no longer a standard diagnostic procedure in prostate cancer. Varenhorst et al showed that bone scanning was superior to random bone marrow aspiration in staging prostate cancer in 1983. 13 Bone scans are the most sensitive bone imaging technique our patients routinely undergo, and bone marrow aspiration and trephine can be done by a trained individual without the aid of interventional radiology. The combined use of bone marrow aspiration and trephines that had been targeted by previously performed bone scans appeared to be a good approach for obtaining cancer cells for research studies, but no published information on the success rates in prostate cancer bone metastases was available. This method yielded a high sampling rate for trephine biopsies (15/20 attempted cases, 15/18 submitted trephines positive), but no yield for aspiration. It is known that trephine biopsy is more sensitive than bone marrow aspiration for the detection of metastatic disease in the bone and bone marrow. 14 However, there is considerable variation within the reported literature on the positive aspiration rate for bone marrow aspiration. The older literature on prostate cancer bone metastases reports positive aspiration rates between 7 and 50% for mixed groups of early and advanced prostate cancer cases (although the majority of positive aspirates were in patients with known bone metastases in all studies). 8 -10,15,16 Early studies did not have the benefit of modern techniques such as immunocytochemistry. The use of immunocytochemistry did not increase the positive marrow aspiration rate in smears of the nine cases assessed here. In micrometastases from breast cancer, immunocytochemical methods can detect tumour cells in marrow/tumour mixtures down to 0.00025%. 17 Positive bone marrow aspiration rates using morphology assessment in patients with known bone metastases from breast cancer show a significant proportion of tumour cells in the aspirate (40%). 18 In prostate cancer patients with known M1 disease, positive aspiration rates varied between 20 and 58% when random biopsies were performed in the older literature. 8, 9, 15, 16 Mansi et al reported moderate to large numbers of cells in the bone marrow aspirate of 11 out of 15 patients (73%) with known bone metastases using a panel of immunohistochemical markers. 11 A previous preliminary study at our centre of prostate cancer patients with positive bone scans showed three of nine aspirates taken by the haematologist contained prostate cancer cells, and only one sample contained cells in large numbers (T Begum, personal communication).
It is difficult to explain the low aspiration rate reported here in comparison to other studies. Tumor load, as indirectly assessed by the combination of serum PSA, 19 bone scan lesion count 20 and FBC results, does not reveal results different to many other patients seen in the clinic with progressive prostate cancer. We did not perform reverse transcriptase polymerase chain reactions on any of the blood samples obtained, and therefore do not have data on circulating tumour load in a more quantitative fashion.
One reason for lower marrow aspiration rates in bone metastases from prostate cancer (and other tumours) has long been recognised. 8 The failure to obtain any material on bone marrow aspiration is usually associated with a trephine biopsy that showed a significant tumour infiltrate and a marked fibrotic reaction within the marrow space. This occurred in four of our samples.
Positive random bone marrow trephine biopsy rates have been previously reported as being positive in five out of 14 cases (36%) by Crisp and five out of six cases (83%) by Spiers. 3 -6 In the biggest series reported by Sy et al, 32 out of 41 patients (78%) with advanced prostate cancer had positive random iliac bone biopsies. In the only other study of prostate cancer patients reporting targeted biopsies, Chua et al obtained 18 out of 19 (95%) positive trephine biopsies in a group of patients with known bone metastases targeted by X-ray guidance (as part of a mixed series of random and image-guided bone marrow biopsies). 3 One reason for the failure of bone marrow trephine biopsy to obtain metastases (apart from significant osteosclerosis) is shown in Figures 1 and 2 . Without image-guided biopsies small lesions (such as those demonstrated) may be difficult to target accurately by clinical sampling alone. The standard diagnostic bone scan used to guide all our biopsies were two-dimensional planar (anteroposterior) images. The absence of information on the depth of the targeted lesion may limit the successful sampling of smaller lesions. Such depth information can be obtained from bone scans by using a tomographic technique on a diagnostic gamma camera (producing images that are very similar to the axial PET view shown in Figure 1B ). Such views are rarely used for diagnostic scans in prostate cancer patients where the information required usually concerns the question are there bone metastases present or not, or have known bone metastases changed over time.
Magnetic resonance imaging of the pelvis and PET bone scanning can also provide information on target lesion depth (with MRI able to be used to measure an accurate depth, Figure 1C ). When there was only a small target lesion, the use of extra information on depth still did not allow a successful biopsy sample to be taken. These imaging modalities are also not routinely available for use on all patients to identify the site of disease in three-dimensions. It is hard to see how the rate of positive biopsies could be increased further using clinical rather than direct radiologically guided biopsies to target small metastatic deposits using the method described.
Magnetic resonance imaging scans have been shown to be a very sensitive method of detecting skeletal metastases compared with conventional bone scintigraphy. 21, 22 Planar bone scintigraphy has recently been compared with 18F PET bone studies by Schirrmeister et al in 44 patients with known prostate (20/44), lung or thyroid carcinoma. 23 The bone scans had a decreased sensitivity for detecting benign and malignant lesions in the bony pelvis compared with 18F PET bone scans. The three 18F PET and pelvic MR images in our study were however not performed for direct comparison of sensitivity or specificity for lesion detection, but rather for further localisation of a known target lesion.
The results of the nanocolloid bone marrow studies on the three patients agree with previously published data. Haddock et al reported nanocolloid bone marrow scintigraphy to be less sensitive than conventional bone scans for the detection of skeletal metastases from carcinoma of the prostate. 24 Bone marrow scans usually reveal cold spots (photon deficient areas due to defects in tracer accumulation) if significant marrow infiltration is present. Hot spots have also been reported due to metastatic disease, but neither metastases nor peripheral marrow expansion due to central marrow failure were seen in the three patients scanned.
In conclusion, we have shown that trephine biopsy can be used to obtain cancer cells from the majority of hormone-resistant prostate cancer patients using previous diagnostic bone scans as a method for targeting bone deposits.
